Tags

Type your tag names separated by a space and hit enter

Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction.
Am J Respir Crit Care Med. 1999 Dec; 160(6):2100-3.AJ

Abstract

beta-adrenoreceptor blockers such as propranolol provoke bronchoconstriction only in asthmatic patients. Although cysteinyl leukotrienes (cLTs) and thromboxane A2 (TXA2) have been proposed to be involved in the pathophysiology of asthma, the role of these lipid mediators in propranolol-induced bronchoconstriction (PIB) has not been evaluated in asthmatics. This study was conducted to elucidate it. Nine patients with stable asthma, in whom a 20% or more decrease in FEV(1) occurred by inhalation of 20 mg/ml or less propranolol, participated in this study. A cLT antagonist, pranlukast (225 mg twice a day), a TXA2 antagonist, seratrodast (80 mg once a day), and placebo were orally given for 2 wk in a randomized and double-blinded manner. The provocative concentration of propranolol causing a 20% fall in FEV(1) (PC(20)) was determined on the last day of each 2-wk treatment. Pranlukast, but not seratrodast, tented to increase FEV(1) compared with placebo (2.14 +/- 0.29 versus 1.99 +/- 0.34 L, p = 0.0543). Pranlukast or seratrodast did not affect the PC(20) in comparison with placebo. We conclude that cLTs or TXA2 are not involved in PIB of asthmatics.

Authors+Show Affiliations

The Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10588635

Citation

Fujimura, M, et al. "Effect of Leukotriene and Thromboxane Antagonist On Propranolol-induced Bronchoconstriction." American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 6, 1999, pp. 2100-3.
Fujimura M, Abo M, Kamio Y, et al. Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. Am J Respir Crit Care Med. 1999;160(6):2100-3.
Fujimura, M., Abo, M., Kamio, Y., Myou, S., Ishiura, Y., Hashimoto, T., & Matsuda, T. (1999). Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine, 160(6), 2100-3.
Fujimura M, et al. Effect of Leukotriene and Thromboxane Antagonist On Propranolol-induced Bronchoconstriction. Am J Respir Crit Care Med. 1999;160(6):2100-3. PubMed PMID: 10588635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction. AU - Fujimura,M, AU - Abo,M, AU - Kamio,Y, AU - Myou,S, AU - Ishiura,Y, AU - Hashimoto,T, AU - Matsuda,T, PY - 1999/12/10/pubmed PY - 2001/7/4/medline PY - 1999/12/10/entrez SP - 2100 EP - 3 JF - American journal of respiratory and critical care medicine JO - Am J Respir Crit Care Med VL - 160 IS - 6 N2 - beta-adrenoreceptor blockers such as propranolol provoke bronchoconstriction only in asthmatic patients. Although cysteinyl leukotrienes (cLTs) and thromboxane A2 (TXA2) have been proposed to be involved in the pathophysiology of asthma, the role of these lipid mediators in propranolol-induced bronchoconstriction (PIB) has not been evaluated in asthmatics. This study was conducted to elucidate it. Nine patients with stable asthma, in whom a 20% or more decrease in FEV(1) occurred by inhalation of 20 mg/ml or less propranolol, participated in this study. A cLT antagonist, pranlukast (225 mg twice a day), a TXA2 antagonist, seratrodast (80 mg once a day), and placebo were orally given for 2 wk in a randomized and double-blinded manner. The provocative concentration of propranolol causing a 20% fall in FEV(1) (PC(20)) was determined on the last day of each 2-wk treatment. Pranlukast, but not seratrodast, tented to increase FEV(1) compared with placebo (2.14 +/- 0.29 versus 1.99 +/- 0.34 L, p = 0.0543). Pranlukast or seratrodast did not affect the PC(20) in comparison with placebo. We conclude that cLTs or TXA2 are not involved in PIB of asthmatics. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/10588635/Effect_of_leukotriene_and_thromboxane_antagonist_on_propranolol_induced_bronchoconstriction_ L2 - https://www.atsjournals.org/doi/10.1164/ajrccm.160.6.9902110?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -